[{"id":"4b1b80e8-bcd8-4a78-8ae1-fe238c0362b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126916","created_at":"2021-01-18T15:24:54.957Z","updated_at":"2025-02-25T15:10:35.328Z","phase":"Phase 3","brief_title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","source_id_and_acronym":"NCT03126916","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 724","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-13"},{"id":"2389ac55-3a18-481d-8919-40b11f2cb668","acronym":"NCI-2017-01069","url":"https://clinicaltrials.gov/study/NCT03192397","created_at":"2021-01-18T15:44:50.740Z","updated_at":"2024-07-02T16:35:00.229Z","phase":"Phase 1/2","brief_title":"Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant","source_id_and_acronym":"NCT03192397 - NCI-2017-01069","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • melphalan • fludarabine IV • captisol-enabled melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 08/21/2023","primary_completion_date":" 08/21/2023","study_txt":" Completion: 05/21/2027","study_completion_date":" 05/21/2027","last_update_posted":"2024-05-29"},{"id":"c7e83498-ae4f-45ae-8bbe-548a13445d7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05013437","created_at":"2021-08-27T13:53:01.565Z","updated_at":"2024-07-02T16:35:11.879Z","phase":"Phase 1","brief_title":"Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma","source_id_and_acronym":"NCT05013437","lead_sponsor":"Koen van Besien","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e captisol-enabled melphalan"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-04-02"},{"id":"13ab5f92-604f-4f3e-802d-435eb5b955ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT03159702","created_at":"2021-01-18T15:34:40.801Z","updated_at":"2024-07-02T16:35:25.709Z","phase":"Phase 2","brief_title":"Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation","source_id_and_acronym":"NCT03159702","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV • captisol-enabled melphalan"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 12/08/2017","start_date":" 12/08/2017","primary_txt":" Primary completion: 11/16/2025","primary_completion_date":" 11/16/2025","study_txt":" Completion: 11/16/2025","study_completion_date":" 11/16/2025","last_update_posted":"2023-12-20"},{"id":"93ce2b77-c902-4ed8-aa0f-a093a173d2f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03342196","created_at":"2021-01-18T16:30:30.021Z","updated_at":"2024-07-02T16:35:26.582Z","phase":"Phase 2","brief_title":"Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation","source_id_and_acronym":"NCT03342196","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV • thiotepa • Kepivance (palifermin) • captisol-enabled melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/21/2018","start_date":" 03/21/2018","primary_txt":" Primary completion: 06/09/2024","primary_completion_date":" 06/09/2024","study_txt":" Completion: 06/09/2025","study_completion_date":" 06/09/2025","last_update_posted":"2023-12-11"},{"id":"f7e16369-1429-45d8-9dba-024985674f87","acronym":"","url":"https://clinicaltrials.gov/study/NCT00080886","created_at":"2021-01-18T00:13:28.893Z","updated_at":"2024-07-02T16:35:34.490Z","phase":"Phase 2","brief_title":"Rituximab, Carmustine; Cytarabine, Etoposide, \u0026 Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00080886","lead_sponsor":"University of Nebraska","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • etoposide IV • carmustine • melphalan • Gliadel Wafer (carmustine implant) • captisol-enabled melphalan"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 05/08/2002","start_date":" 05/08/2002","primary_txt":" Primary completion: 11/01/2005","primary_completion_date":" 11/01/2005","study_txt":" Completion: 03/12/2015","study_completion_date":" 03/12/2015","last_update_posted":"2023-10-06"},{"id":"1edc2e61-bcd5-42c9-88f7-a4d3a80395fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02909036","created_at":"2021-01-18T14:16:39.145Z","updated_at":"2024-07-02T16:35:35.026Z","phase":"Phase 1","brief_title":"Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.","source_id_and_acronym":"NCT02909036","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • Neulasta (pegfilgrastim) • captisol-enabled melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-10-03"},{"id":"46e4deaa-8f21-4cac-8410-39826ed5483d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00006695","created_at":"2021-01-17T23:54:05.754Z","updated_at":"2024-07-02T16:35:38.269Z","phase":"Phase 2","brief_title":"Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00006695","lead_sponsor":"University of Nebraska","biomarkers":" CD20 • CD34","pipe":"","alterations":" ","tags":["CD20 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • carmustine • melphalan • Bexxar (iodine I 131 tositumomab) • captisol-enabled melphalan"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 04/01/2000","start_date":" 04/01/2000","primary_txt":" Primary completion: 09/01/2005","primary_completion_date":" 09/01/2005","study_txt":" Completion: 12/16/2014","study_completion_date":" 12/16/2014","last_update_posted":"2023-09-01"},{"id":"e5847a40-5b30-420c-89e4-cd5a71acd410","acronym":"","url":"https://clinicaltrials.gov/study/NCT02756572","created_at":"2022-01-21T22:01:58.163Z","updated_at":"2024-07-02T16:36:20.983Z","phase":"Phase 2","brief_title":"Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms","source_id_and_acronym":"NCT02756572","lead_sponsor":"University of Washington","biomarkers":" HLA-B","pipe":"","alterations":" ","tags":["HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • sirolimus • mitoxantrone • cladribine • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • captisol-enabled melphalan"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 09/22/2016","start_date":" 09/22/2016","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2021-11-08"},{"id":"bffc5c29-07f6-478d-be68-cc0a37c1a4a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01660633","created_at":"2021-01-18T07:10:14.149Z","updated_at":"2024-07-02T16:36:45.812Z","phase":"Phase 2b","brief_title":"Safety \u0026 Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation","source_id_and_acronym":"NCT01660633","lead_sponsor":"Acrotech Biopharma LLC","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • captisol-enabled melphalan"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 02/01/2014","primary_completion_date":" 02/01/2014","study_txt":" Completion: 08/01/2014","study_completion_date":" 08/01/2014","last_update_posted":"2020-04-21"},{"id":"04790d5d-db65-48d1-8dcc-79ebf1b22b0c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03328936","created_at":"2021-01-18T16:26:18.790Z","updated_at":"2024-07-02T16:36:49.719Z","phase":"Phase 2","brief_title":"Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant","source_id_and_acronym":"NCT03328936","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • captisol-enabled melphalan"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2018","start_date":" 09/01/2018","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 03/31/2021","study_completion_date":" 03/31/2021","last_update_posted":"2020-02-21"},{"id":"fc8f2a89-dda3-49c1-99d5-1f1ff5ac272e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00925782","created_at":"2021-01-18T03:35:08.019Z","updated_at":"2025-02-25T14:14:30.771Z","phase":"Phase 2a","brief_title":"PK Study of Melphalan HCL \u0026 Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation","source_id_and_acronym":"NCT00925782","lead_sponsor":"Acrotech Biopharma LLC","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • captisol-enabled melphalan"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 01/01/2010","start_date":" 01/01/2010","primary_txt":" Primary completion: 06/01/2011","primary_completion_date":" 06/01/2011","study_txt":" Completion: 07/01/2011","study_completion_date":" 07/01/2011","last_update_posted":"2019-12-17"}]